
Bavarian Nordic has administered the first shot of its RSV vaccine in a phase III trial with older adults, and the global study is therefore now underway, the company has announced in a press release.
The trial will assess the efficacy of Bavarian’s candidate, MVA-BN RSV, in older patients with lower-respiratory tract disease caused by respiratory syncytial virus (RSV).
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app